7/4/2006
New Emerging Drugs in Soft Tissue Sarcoma
Amalia Milanoa, Gaetano Apicea, Ettore Ferraria, Flavio Faziolia, Vincenzo de Rosaa, Antonella Salzano de Lunaa, Rosario Vincenzo Iaffaiolia and Francesco Caponigro , a, aIstituto Nazionale Tumori, Fondazione G. Pascale, Via M. Semmola, 80131 Napoli, Italy Accepted 28 December 2005. Available online 13 March 2006.
Abstract
Doxorubicin and ifosfamide are the two most active drugs in the treatment of patients with advanced, soft tissue sarcoma (STS) of most histologic subtypes, aside from gastrointestinal stromal tumor (GIST). However, after failure of these drugs, alone or in combination, patients with advanced STS have few therapeutic options and the search for new active drugs is well worth pursuing.
ET-743, a DNA minor groove binder, which blocks cell cycle progression in G2/M phase through a p53-independent apoptotic process, represents the most promising among novel compounds in STS, since recently completed phase II trials have consistently shown high survival, in spite of the relatively low incidence of major objective responses. The potential for combination with other active compounds further increases the appeal of ET-743.
Imatinib mesylate is being tested also in STS other than GIST, which can overexpress one or more of the tyrosine kinases inhibited by imatinib; however, negative data have recently been presented.
Clinical studies with a number of other compounds are ongoing or planned. However, investigators involved in the management of patients with advanced STS are to be increasingly aware of the emergence of new molecular targets and genetic profiles in different histologic subtypes, according to which treatment strategies should be adapted.
Critical Reviews in Oncology/Hematology Volume 59, Issue 1, July 2006, Pages 74-84
Keywords: ET-743; Imatinib; New drugs; Soft tissue sarcoma
Corresponding author. Tel.: +39 081 5903362; fax: +39 081 5903822.
To view entire article, click here: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T5S-4JG5FFX-3&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=7ca402af15bddeb8a6f2300f11489486
|
|
 |
Thursday, June 29, 2000
Managing Chemotherapy Side Effects Can Lead to a Summer of Strength
view
|
Friday, November 10, 2000
Synovial Sarcoma: A Clinicopathologic, Staging, and Prognostic Assessment
view
|
Friday, January 03, 2003
Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells
view
|
Thursday, April 10, 2003
Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome
view
|
Sunday, May 01, 2005
Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors
view
|
Thursday, May 05, 2005
A Look At Bone Sarcomas Past and Present
view
|
Wednesday, August 10, 2005
Rhabdomyosarcoma: New Windows of Opportunity
view
|
Sunday, September 04, 2005
The Growing Role of the mTOR Pathway
view
|
Monday, September 12, 2005
Cancer Treatment Related Changes in Cognitive Function (a.k.a. "Chemo Brain")
view
|
Tuesday, July 04, 2006
New Emerging Drugs in Soft Tissue Sarcoma
view
|
Thursday, August 24, 2006
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
view
|
|
Tuesday, September 05, 2006
Soft Tissue Sarcoma
|
Thursday, January 25, 2007
Cancer Pathway Exposed
view
|
Sunday, May 20, 2007
Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group
view
|
Monday, May 28, 2007
Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future
view
|
Wednesday, July 11, 2007
Survival for Soft Tissue Sarcoma Patients Improved at High-volume Centers
view
|
|
Tuesday, September 04, 2007
Anatomy of a Visit - Behind the Waiting Room Walls in the UM Cancer Center
|
Wednesday, September 12, 2007
Kaposi Sarcoma
view
|
Thursday, September 13, 2007
Ewing Sarcoma
view
|
Thursday, November 08, 2007
Gastrointestinal Stromal Tumours and Imatinib
view
|
|
Friday, November 09, 2007
13th Annual CTOS SARC Agenda Book
|
Friday, November 16, 2007
Pediatric sarcomas occurring in adults
view
|
Wednesday, January 02, 2008
SARC: An Effort to Perform Clinical Trials More Efficiently and Effectively for People with Sarcoma
view
|
Saturday, January 05, 2008
Therapeutic Potential of Directed Tyrosine Kinase Inhibitor Therapy in Sarcomas
view
|
Monday, January 28, 2008
Chordoma: The Nonsarcoma Primary Bone Tumor
view
|
|
|
|